Merck Announces Data For V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed For Adults
Merck Announces Data For V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed For Adults
默沙東公佈了專爲成人設計的V116、在研的21價肺炎球菌偶聯疫苗的數據
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
最新的 3 期 STRIDE-10 試驗在歐洲臨床微生物學和傳染病學會以口頭陳述的形式發表
Results build on the data supporting the clinical profile of V116 for adults
結果建立在支持成人V116臨床特徵的數據基礎上
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。